10x Genomics director sells 7,579 TXG shares

10x Genomics, Inc. director Sarah A. Teichmann reported an open-market sale of 7,579 shares of Class A Common Stock at $19.41 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

10x Genomics, Inc. director Sarah A. Teichmann reported an open-market sale of 7,579 shares of Class A Common Stock at $19.41 per share. After this transaction, she directly holds 26,780 shares. The sale was executed under her pre-arranged Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 7,579 shares

Net Sell 1 txn

Insider Teichmann Sarah A.

Role Director

Sold 7,579 shs ($147K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	7,579	$19.41	$147K

Holdings After Transaction: Class A Common Stock — 26,780 shares (Direct)

Footnotes (1)

F1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 26, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did 10x Genomics (TXG) report for Sarah A. Teichmann?

Sarah A. Teichmann reported selling 7,579 shares of 10x Genomics Class A Common Stock in an open-market transaction at $19.41 per share. This sale is disclosed in a Form 4 insider trading report filed for the company.

At what price were the 10x Genomics (TXG) shares sold in this Form 4?

The reported sale was executed at a price of $19.41 per share for 10x Genomics Class A Common Stock. This per-share transaction price comes directly from the Form 4 insider trading disclosure.

How many 10x Genomics (TXG) shares does Sarah A. Teichmann hold after the sale?

Following the reported transaction, Sarah A. Teichmann directly holds 26,780 shares of 10x Genomics Class A Common Stock. This post-transaction ownership figure is stated in the Form 4 filing as the total shares following the sale.

Was the 10x Genomics (TXG) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 notes the sale was effected under Sarah A. Teichmann’s Rule 10b5-1 trading plan. The plan was previously adopted and governs pre-scheduled transactions in 10x Genomics shares.

What role does Sarah A. Teichmann have at 10x Genomics (TXG)?

Sarah A. Teichmann is identified as a director of 10x Genomics, Inc. in the Form 4 filing. The report classifies her as a director and shows the disclosed stock sale as directly owned shares.

Is the 10x Genomics (TXG) insider transaction classified as a sale or purchase?

The Form 4 classifies the transaction as a sale of non-derivative securities. It uses transaction code “S” and describes it as an open-market sale of 10x Genomics Class A Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/27/2026 - 04:01 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teichmann Sarah A.

(Last)

(First)

(Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

94588

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	02/25/2026		S⁽¹⁾		7,579	D	$19.41	26,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 26, 2025.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Randy Wu, as Attorney-in-Fact for Sarah A. Teichmann	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR